

Novartis Nilotinib Compassionate Use (CU) Program

- Patients who are not able to participate in ongoing nilotinib clinical trials may be able to receive nilotinib on a compassionate use basis.
- Requests for compassionate use will only be considered when the request is sent to Novartis by the treating physician through a secure, business email.
- Patients will be evaluated for eligibility based on pre-defined inclusion/exclusion criteria.
- Requests should be routed to the local, country Novartis medical representative for submission to the following email address:

Nilotinib.CompassionateUse@Novartis.com